240 related articles for article (PubMed ID: 2771633)
1. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
Guilhot F; Dreyfus B; Desmarest MC; Giraud C; Huret JL; Brizard A; Tanzer J
Nouv Rev Fr Hematol (1978); 1989; 31(2):171-3. PubMed ID: 2771633
[TBL] [Abstract][Full Text] [Related]
2. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S
Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976
[TBL] [Abstract][Full Text] [Related]
3. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.
Guilhot F; Chastang C; Michallet M; Guerci A; Harousseau JL; Maloisel F; Bouabdallah R; Guyotat D; Cheron N; Nicolini F; Abgrall JF; Tanzer J
N Engl J Med; 1997 Jul; 337(4):223-9. PubMed ID: 9227927
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
Sacchi S; Kantarjian HM; O'Brien S; Beran M; Koller C; Pierce S; Kornblau S; Estey E; Keating MJ; Talpaz M
Leukemia; 1997 Oct; 11(10):1610-6. PubMed ID: 9324278
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
[TBL] [Abstract][Full Text] [Related]
6. A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results.
Guilhot F; Abgrall JF; Harousseau JL; Bauters F; Brice P; Dine G; Tilly H; Ifrah N; Cassasus P; Rochant H
Leuk Lymphoma; 1993; 11 Suppl 1():181-3. PubMed ID: 8251893
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study.
Thaler J; Hilbe W; Apfelbeck U; Linkesch W; Sill H; Seewann H; Pont J; Bernhart M; Stöger M; Niessner H; Abbrederis K; Geissler D; Hausmaninger H; Lin W; Ludwig H; Lang A; Duba C; Fluckinger T; Greil R; Grünewald K; Konwalinka G; Niederwieser D; Fridrik M
Leuk Res; 1997 Jan; 21(1):75-80. PubMed ID: 9029189
[TBL] [Abstract][Full Text] [Related]
8. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
[TBL] [Abstract][Full Text] [Related]
9. Evolving approaches with interferon alfa in chronic myelogenous leukemia.
Morra E; Alimena G; Lazzarino M; Liberati AM; Montefusco E; Bernasconi P; Mancini M; Donti E; Merante S; Caricchi P
Semin Hematol; 1993 Jul; 30(3 Suppl 3):26-7. PubMed ID: 8235701
[No Abstract] [Full Text] [Related]
10. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
Anger B; Porzsolt F; Leichtle R; Heinze B; Bartram C; Heimpel H
Blut; 1989 Jun; 58(6):275-8. PubMed ID: 2736308
[TBL] [Abstract][Full Text] [Related]
11. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
[TBL] [Abstract][Full Text] [Related]
12. Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia.
Arthur CK; Ma DD
Acta Haematol; 1993; 89 Suppl 1():15-21. PubMed ID: 8475667
[TBL] [Abstract][Full Text] [Related]
13. [Hematologic and cytogenetic response to treatment in patients with chronic myeloid leukemia].
Tóthová E; Fricová M; Stecová N; Kafková A; Mudronová B; Svorcová E; Guman T; Raffac S; Hlebasková M
Cas Lek Cesk; 2000 Jul; 139(14):437-9. PubMed ID: 11048406
[TBL] [Abstract][Full Text] [Related]
14. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
Sacchi S; Kantarjian HM; Freireich EJ; O'Brien S; Cortes J; Rios MB; Kornblau S; Giles FJ; Koller C; Gajewski J; Talpaz M
Leuk Lymphoma; 1999 Nov; 35(5-6):483-9. PubMed ID: 10609785
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients.
Ferrajoli A; Liberati AM; Caricchi P; Donti E; Morra E; Lazzarino M; Betti AR; Bernasconi P; Saglio G
Eur J Haematol; 1995 Sep; 55(3):184-8. PubMed ID: 7672091
[TBL] [Abstract][Full Text] [Related]
16. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetics and molecular analysis in chronic myelogenous leukemia patients treated by interferon and chemotherapy.
Guilhot F; Ahmad M; Mahon FX; Dreyfus B; Brizard A; Huret JL; Kitzis A; Tanzer J
Nouv Rev Fr Hematol (1978); 1990; 32(5):287-8. PubMed ID: 2099398
[TBL] [Abstract][Full Text] [Related]
19. FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Martinelli G; Testoni N; Zuffa E; Visani G; Zinzani PL; Zaccaria A; Farabegoli P; Arpinati M; Amabile M; Tura S
Leuk Lymphoma; 1996 Jun; 22(1-2):173-6. PubMed ID: 8724545
[TBL] [Abstract][Full Text] [Related]
20. A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside , preliminary results.
Guilhot F; Lamagnère JP; Harousseau JL; Tilly H; Casassus P; Ifrah N; Rochant H; Bauters F; Dine G; Tanzer J
Eur J Cancer; 1991; 27 Suppl 4():S26. PubMed ID: 1799470
[No Abstract] [Full Text] [Related]
[Next] [New Search]